Cartesian Therapeutics, Inc. — Director's Dealing 2023

Nov 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2023-11-13

Reporting Person: Davis Blaine (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-13	Employee Stock Option (right to buy)	$1.27	D	1250000	Disposed	2032-11-27	Common Stock (1250000)	Direct

Footnotes

F1: This option, which provided for vesting as to 25% on November 28, 2023 with the remainder of the underlying shares vesting in 36 equal monthly installments thereafter, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for a cash payment of $987,500, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.